Real-world data show erenumab and galcanezumab effectively reduce migraine frequency in patients unresponsive to onabotulinumtoxinA, indicating their importance in treatment.
Key Points
The study aims to compare the effectiveness of erenumab and galcanezumab in reducing chronic migraine frequency in patients resistant to onabotulinumtoxinA.
Conducted a real-world comparative study
Included patients with chronic migraine refractory to onabotulinumtoxinA
Assessed migraine frequency and triptan use before and after treatment with both interventions
Both erenumab and galcanezumab led to sustained reductions in migraine frequency
High responder rates were observed for both treatments
Triptan use decreased significantly among patients receiving anti-CGRP monoclonal antibodies